Insulinoma is the most common functional endocrine pancreatic tumor in dogs, with an average age at diagnosis of 9-10 years. Large and giant breed dogs are overrepresented, particularly German Shepherds, Irish Setters, Golden Retrievers, and Standard Poodles. Use the Dextrose Calculator for emergency hypoglycemia management and the Internal Medicine Specialist for case-specific treatment planning.
Insulinomas are functional beta-cell neoplasms of the pancreas that secrete insulin autonomously, independent of blood glucose concentration. This inappropriate insulin secretion drives persistent or episodic hypoglycemia. In dogs, insulinomas are almost always malignant (carcinomas), with approximately 50% already metastatic to regional lymph nodes or liver at the time of surgery.
Large breed dogs over 8 years of age are most commonly affected. The tumor is rare in cats. While insulinomas are typically solitary pancreatic nodules (1-3 cm), they may be too small to detect on imaging, and multiple nodules can occasionally occur.
Clinical signs result from neuroglycopenia (insufficient glucose delivery to the brain) and counter-regulatory catecholamine release. Episodes are characteristically intermittent and often triggered by fasting, exercise, or excitement.
Common signs include episodic weakness, ataxia, disorientation, muscle tremors, collapse, and seizures. Between episodes, dogs often appear completely normal. Some owners report subtle behavioral changes such as increased appetite or exercise intolerance. Whipple's triad supports the diagnosis: (1) clinical signs consistent with hypoglycemia, (2) documented low blood glucose at the time of signs, and (3) resolution of signs with glucose administration.
Warning: Seizures from insulinoma-induced hypoglycemia can be life-threatening. If blood glucose drops below 30-40 mg/dL, administer a dextrose bolus immediately. Do NOT give oral glucose syrup to a seizing patient due to aspiration risk. Use the Dextrose Calculator for precise IV bolus dosing.
The cornerstone of insulinoma diagnosis is demonstrating inappropriately elevated insulin in the face of hypoglycemia. A single fasting blood sample showing glucose <60 mg/dL with concurrent insulin within or above normal range is highly suggestive. Insulin should be suppressed when glucose is low; failure to suppress is pathological.
| Diagnostic Test | Expected Finding | Clinical Notes |
|---|---|---|
| Paired insulin:glucose | Insulin normal/high with glucose <60 mg/dL | Gold standard; fast 4-8 hours if needed |
| Amended insulin:glucose ratio (AIGR) | AIGR >30 suggestive | AIGR = (insulin × 100) ÷ (glucose - 30) |
| Abdominal ultrasound | Pancreatic mass, hepatic metastases | Sensitivity only 30-50%; small tumors easily missed |
| CT with contrast | Enhancing pancreatic nodule | Triple-phase CT preferred; sensitivity 60-75% |
| Fructosamine | Low (<250 µmol/L) | Reflects chronic hypoglycemia over 2-3 weeks |
A normal insulin level in the face of hypoglycemia is still abnormal. Insulin should be appropriately suppressed (near zero) when glucose is low. Interpret insulin relative to glucose, not in isolation.
Acute hypoglycemic crises require immediate intervention. Administer a 50% dextrose bolus at 0.5-1 mL/kg IV, diluted 1:2 or 1:4 with saline, over 5-10 minutes. Avoid bolusing undiluted 50% dextrose as it is hyperosmolar and can cause phlebitis and tissue necrosis if extravasated.
Following the bolus, initiate a dextrose constant rate infusion (CRI) at 2.5-5% in IV fluids. Monitor blood glucose every 1-2 hours and titrate the CRI to maintain glucose at 60-100 mg/dL. Avoid overcorrection, as elevated glucose stimulates further insulin release from the tumor, potentially worsening rebound hypoglycemia.
Warning: Avoid giving concentrated oral glucose or excessive dextrose boluses. Rapid glucose elevation triggers exaggerated insulin secretion from the insulinoma, causing dangerous rebound hypoglycemia. Feed frequent small, high-protein, complex-carbohydrate meals instead of simple sugars.
Medical therapy is indicated preoperatively, for inoperable tumors, or when metastatic disease is present. The primary medications include:
Prednisone (0.25-2 mg/kg PO BID): Increases hepatic gluconeogenesis and promotes peripheral insulin resistance. Start at a low dose and titrate upward as needed. Side effects include PU/PD, polyphagia, and potential iatrogenic Cushing's syndrome.
Diazoxide (5-30 mg/kg PO BID): A benzothiadiazide that inhibits pancreatic insulin secretion, enhances hepatic gluconeogenesis, and decreases cellular glucose uptake. This is the most effective medical therapy. It can be expensive and may cause anorexia or vomiting. Check the Drug Formulary for current dosing guidelines.
Octreotide (10-40 mcg/dog SC BID-TID): A somatostatin analog that can suppress insulin secretion. Response is variable and often short-lived in dogs.
Partial pancreatectomy is the treatment of choice for localized insulinoma. Surgery provides histological diagnosis, staging, and debulking even when metastases are present. At surgery, the entire abdomen should be explored, including systematic palpation and visualization of the pancreas, regional lymph nodes, and liver.
| Stage | Description | Median Survival |
|---|---|---|
| Stage I | Tumor confined to pancreas | 14-18 months |
| Stage II | Regional lymph node metastasis | 12 months |
| Stage III | Distant metastasis (liver, peritoneum) | 6 months |
Postoperative complications include pancreatitis (10-15%) and transient hyperglycemia or diabetes mellitus from beta-cell atrophy. Monitor blood glucose closely for 48-72 hours postoperatively. Many dogs become normoglycemic for months after surgery before hypoglycemia recurs from metastatic disease progression.
Regardless of treatment modality, insulinoma carries a guarded long-term prognosis due to its malignant behavior. However, many dogs enjoy a good quality of life for months to over a year with appropriate management. Key elements include frequent small meals (4-6 times daily) of high-protein, complex-carbohydrate diets, avoidance of fasting and strenuous exercise, and regular blood glucose monitoring.
Owners should keep corn syrup at home for emergencies (rub on gums if dog is conscious and not seizing) and have a plan for veterinary emergency access. Serial imaging every 3-4 months helps track metastatic progression.
- Insulinoma presents as episodic hypoglycemia in middle-aged to older large-breed dogs.
- Diagnosis requires demonstrating inappropriately normal or elevated insulin during documented hypoglycemia.
- Emergency treatment is IV dextrose bolus followed by CRI; avoid overcorrection that triggers rebound hypoglycemia.
- Diazoxide is the most effective medical therapy for long-term glucose stabilization.
- Surgical exploration with partial pancreatectomy is recommended even when metastases are suspected.
- Feed frequent small, high-protein meals and avoid fasting and vigorous exercise.